BJOG : an international journal of obstetrics and gynaecology · 2004
The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kingman C E C, Kadir R A, Lee C A, Economides D L
Аннотация
BACKGROUND: The levonorgestrel-releasing intrauterine system (LNG-IUS) is used commonly by gynaecologists as a contraceptive and to treat menorrhagia. However, its efficacy has not been examined in women with inherited bleeding disorders.
DESIGN: A prospective pilot study.
SETTING: A teaching hospital in north London with a designated haemophilia centre.
POPULATION: Female patients with a known inherited bleeding disorder.
METHODS: Sixteen women with subjective and objective menorrhagia caused by inherited bleeding disorders (13 von Willebrand's Disease, two factor XI deficiency and one Hermansky-Pudlak syndrome), who had previously undergone unsuccessful medical treatment were followed up for nine months after LNG-IUS insertion. Bleeding was measured by pictorial chart and haemoglobin concentration.
RESULTS: All women reported that their periods were improved, pictorial chart scores were lower and 56% became amenorrhoeic. None reported side effects.
CONCLUSION: The LNG-IUS is well tolerated and effective and improves quality of life.
DESIGN: A prospective pilot study.
SETTING: A teaching hospital in north London with a designated haemophilia centre.
POPULATION: Female patients with a known inherited bleeding disorder.
METHODS: Sixteen women with subjective and objective menorrhagia caused by inherited bleeding disorders (13 von Willebrand's Disease, two factor XI deficiency and one Hermansky-Pudlak syndrome), who had previously undergone unsuccessful medical treatment were followed up for nine months after LNG-IUS insertion. Bleeding was measured by pictorial chart and haemoglobin concentration.
RESULTS: All women reported that their periods were improved, pictorial chart scores were lower and 56% became amenorrhoeic. None reported side effects.
CONCLUSION: The LNG-IUS is well tolerated and effective and improves quality of life.